4 year highest close., page-84

Thanks BSW, One last detail. Once the FDA have fully evaluated OXYPATCH Phase 3 Data, which is all about non-toxic (skin) delivery of constant therapeutic blood levels of OXY, they will understand the brilliance and high performance capabilities of this TPM-3M-Patch technology.

Does that mean it is likely that other drugs that require Therapeutic Blood Levels (ie:genetics) will only require dose ranging trials to tune up the patch for each differant drug the short Phase 3 trial for approvals.

The FDA don't ask for long trials for NEEDLES for every drug, when does TPM patch achieve delivery status for the drugs it works with.

I doubt if most observers are aware just how valuable this TPM -Patch technology has become. Because after OXY deal, several other deals may well be in the queue for ANTI-PShycotics etc.

Thanks for your comments.